Table 2.
X chromosome genes that may drive the phenotypic impacts of variation in Xi copy number
| Region | Gene symbol | Gene name | NPY gene symbol | ΔEX |
Gene constraint (average % ranking)a | Disease associations |
|||
|---|---|---|---|---|---|---|---|---|---|
| LCL | Fib. | Phenotype | Inheritanceb | MIM # | |||||
| NPX | KDM6A | lysine demethylase 6A | UTY | 0.83 | 0.45 | 93.3 | Kabuki syndrome | XLD | 300867 |
| KDM5C | lysine demethylase 5C | KDM5D | 0.73 | 0.58 | 90.3 | Claes-Jensen syndrome | XLR | 300534 | |
| SMC1A | structural maintenance of chromosomes 1A | – | 0.58 | 0.43 | 87.6 | Cornelia de Lange syndrome; developmental and epileptic encephalopathy | XLD | 300590, 301044 | |
| ZFX | zinc finger protein X-linked | ZFY | 0.45 | 0.47 | 83.0 | – | – | – | |
| RBBP7 | RB-binding protein 7, chromatin remodeling factor | – | 0.01 | 0.29 | 82.5 | – | – | – | |
| DDX3X | DEAD-box helicase 3 X-linked | DDX3Y | 0.26 | 0.16 | 89.2 | syndromic IDD,c Snijders Blok type | XLD, XLR | 300958 | |
| CDK16 | Cyclin dependent kinase 16 | – | 0.09 | 0.24 | 83.8 | – | – | – | |
| DLG3 | discs large MAGUK scaffold protein 3 | – | 0.18 | 0.07 | 82.8 | IDD | XLR | 300580 | |
| USP9X | ubiquitin-specific protease 9 X-linked | USP9Y | 0.14 | 0.17 | 94.4 | IDD | XLR, XLD | 300919, 300968 | |
| BCOR | BCL6 corepressor | – | 0.12 | 0.01 | 91.1 | oculofaciocardiodental syndrome | XLD | 300166 | |
| PAR1 | SLC25A6 | solute carrier family 25 member 6 | N/A | 1.0 | 0.74 | 67.4 | – | – | – |
| SHOX | short stature homeobox | N/A | N/Ad | N/A | 58.4 | Leri-Weill dyschondrosteosis; Langer mesomelic dysplasia; short stature idiopathic familial | PD, PR | 127300, 249700, 300582 | |
Gene constraint percentile ranking is calculated for NPX genes relative to all annotated NPX genes and for PAR1 genes relative to all PAR and autosomal genes.
XLD, X-linked dominant; XLR, X-linked recessive; PD, pseudoautosomal dominant; PR, pseudoautosomal recessive.
IDD, intellectual developmental disorder.
SHOX is not expressed in fibroblasts or LCLs but is included because its dosage has been conclusively linked to height in individuals with sex chromosome aneuploidy.